Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
-23.32%
Shrank
—
—
Shrank
—
1 Year
Score—
Net Growth-23.32%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
—
-99.74%
40%
—
—
Never
—
5 Years
Score—
Net Growth-99.74%
Net Trend40%
Net Income Consistency—
Rev Growth—
Rev TrendNever
Revenue Consistency—
Explore the 2021 public Archive ranking →
Where Tenax Therapeutics Inc has ranked, year by year
Measure
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- TENX
2010: 100.0% · 2021: 99.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 1.89 | — |
1 Year2025-09-30 | $ 7.61 | -75.16% |
5 Years2021-09-30 | $ 2.83K | -99.93% |
10 Years2016-09-30 | $ 74.08K | -100.00% |
20 Years2006-09-29 | $ 1000K | -100.00% |
30 Years1996-09-30 | $ 1000K | -100.00% |
All Time1997-01-02 | $ 1000K | -100.00% |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | 20 Years2006-09-29 | 30 Years1996-09-30 | All Time1997-01-02 |
|---|---|---|---|---|---|---|---|
| Price | $ 1.89 | $ 7.61 | $ 2.83K | $ 74.08K | $ 1000K | $ 1000K | $ 1000K |
| Return | — | -75.16% | -99.93% | -100.00% | -100.00% | -100.00% | -100.00% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 0.00 | -$ 64M | $ 117M |
| 2025 | $ 0.00 | -$ 52M | $ 97M |
| 2024 | $ 0.00 | -$ 17M | $ 94M |
| 2023 | $ 0.00 | -$ 7M | $ 9M |
| 2022 | $ 0.00 | -$ 11M | $ 2M |
| 2021 | $ 0.00 | -$ 32M | $ 5M |
| 2020 | $ 0.00 | -$ 9M | $ 6M |
| 2019 | $ 0.00 | -$ 8M | $ 5M |
| 2018 | $ 0.00 | -$ 6M | $ 12M |
| 2017 | $ 0.00 | -$ 8M | $ 7M |
| 2016 | $ 0.00 | -$ 43M | $ 13M |
| 2015 | $ 49.29K | -$ 14M | $ 20M |
| 2014 | $ 49.29K | -$ 14M | $ 58M |
| 2013 | $ 288.73K | -$ 19M | $ 58M |
| 2012 | $ 288.73K | -$ 19M | $ 6M |
| 2011 | $ 415.03K | -$ 15M | $ 3M |
| 2010 | $ 322.35K | -$ 10M | $ 632.71K |
| 2009 | $ 47.39K | -$ 10M | $ 2M |
| 2008 | -$ 6M | $ 4M | |
| 2007 | -$ 24.13K | -$ 3M | $ 940.24K |
| 2006 | -$ 25.63K | -$ 3M | $ 382.00 |
| 2005 | -$ 25.63K | -$ 2M | $ 588.76K |
| 2004 | -$ 2M | $ 1M | |
| 2003 | -$ 2M | $ 722.54K | |
| 2002 | -$ 3M | $ 524.43K | |
| 2001 | $ 1.00 | -$ 1M | $ 2M |
| 2000 | $ 1.00 | -$ 1M | $ 5M |
| 1999 | $ 1.00 | -$ 911.34K | $ 200K |
| 1998 | $ 1.00 | -$ 800K | $ 740.22K |
| IPO1997 | -$ 1M | $ 53.86K |
Tenax Therapeutics Inc fundamental performance
Between 2005 and 2025, revenue went from -$ 25.63K to $ 0.00 and net income went from -$ 2M to -$ 52M. Revenue increased in 3 of those 20 years; net income in 6.
Tenax Therapeutics Inc currently holds a 20-year HDB Score of 1.3 out of 10. How the HDB Score is calculated.
Membership
Continue TENX’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
